CELL INTELLIGENCE · 肿瘤细胞治疗研究

抗 BCMA/GPRC5D CAR-T 细胞用于伴骨外髓外病变的复发/难治性多发性骨髓瘤患者

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

携带 BLM 突变的 DLBCL 患者在接受 CD19/CD22 双特异性 CAR-T 细胞治疗后发生继发性外周 T 细胞淋巴瘤

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.

复发/难治性 B 细胞非霍奇金淋巴瘤中 CD19/20 CAR-T 疗法的临床结局与空间转录组图谱

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.

双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。

CD3ɛ 纳米抗体工程化细胞外囊泡驱动体内生成分泌 TCE 的 CAR-T 用于具有记忆反应和最小免疫原性的实体瘤治疗

CD3ɛ Nanobody-Engineered Extracellular Vesicles Driving In Vivo Generation of TCE-secreting CAR-Ts for Solid Tumor Therapy With Memory Response and Mi

双特异性 ANXA2/CD147 CAR-T 细胞疗法治疗骨肉瘤

Bispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma.

SLC7A11 与 PD-L1 共表达增高与结外自然杀伤 T 细胞淋巴瘤患者不良预后相关

The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.

PD-1 与 NKG2A 双重阻断预防 NK 细胞衰老并重编程胰腺癌免疫抑制微环境

Dual blockade of PD-1 and NKG2A prevents NK cell senescence and reprograms the immunosuppressive microenvironment in pancreatic cancer.

双重靶向 OX40 和 IL-2 受体通过清除肿瘤浸润 Treg 与促进 CD8(+) T 细胞增殖增强抗肿瘤活性

Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8(+) T-cell proliferation.

我们的研究揭示了一种新的 IL-2 设计方法，可解决现有策略的若干关键缺陷，并阐明了 aOX40-mIL2-Fc 疗法的细胞机制。

增强 PD-L1 靶向提升 FOLR1- CAR NK92 细胞对卵巢癌的杀伤活性

Enhanced PD-L1 targeting boosts the cytotoxic activity of FOLR1- CAR NK92 cells against ovarian cancer.

仿生纳米免疫疗法增强时空 PANoptosis 并重塑促结缔组织增生性肿瘤微环境

Biomimetic nanoimmunotherapy boosts spatiotemporal PANoptosis and reshapes desmoplastic tumor microenvironment.